We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Futura Medical Plc | FUM | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 3.80 | 10.33% | 40.60 | 16:35:10 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 37.80 | 37.80 | 40.00 | 40.60 | 36.80 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 05/5/2024 11:30 by takeiteasy You harp on endlessly about the Reckitt case in law as if it has any sort of relevance here - if you have read the document you will see in 5 minutes it has no bearing on our situation at all. The firm had no contract, no legal approvals and was in a very early stage of negotiations where the actual product specs were subject to confirmation.We have a deal here, regulatory approvals and a proven product launched in multiple countries. Please let this one rest - just accept it is meaningless to investors here. When you have a copy of the FUM patents and have checked with a professional lawyer then you may realise that actually your endless speculation here is without merit - you do not even know what FUM are basing their patent claims on - so wild speculation is quite meaningless. |
Posted at 04/5/2024 10:03 by mdi Yea placebo effects do wear off for many and its yet to be determined how sustainable the market size is for these non medicated hydroalcoholic gels in ED. Not even Futura can comment or give estimates on repeat sales. Yet clearly in the Futura results its been proven sales fell off substantially after the launch hype and when the partners back off marketing.Wellness Investors: Beware The Placebo Trap Whats the problem with placebos? Placebo effects tend to wear off, and when they do, your customers will drop off. This forces tremendous spending on acquisition since it can cost five times as much to acquire new customers than keep current ones. Since repeat customers generate more than half of the revenue for a majority of businesses, pretty packaging of a placebo will likely struggle to sustain sales. Perhaps the boom and bust commonly seen with wellness brands isn’tt due to the hype cycle, but rather the placebo cycle. But one thing is for sure. There is no real enforceable barriers to entry. So if a sustainable profitable market does exist for these placebo hydroalcoholic gels then others who already are established in the market with similar products will enter the market too. Either way its unlikely Futura will ever get enough revenue itself from the sustainable annual sales to justify its current market cap Could a 'Placebo' Become the Next Big ED Treatment? |
Posted at 02/5/2024 14:50 by mdi Similar to the ‘successful&rsEroxon revenue was £1.7m in April/May 2023 and then only £1.4m in the following 6 months Wellness Investors: Beware The Placebo Trap Whats the problem with placebos? Placebo effects tend to wear off, and when they do, your customers will drop off. This forces tremendous spending on acquisition since it can cost five times as much to acquire new customers than keep current ones. Since repeat customers generate more than half of the revenue for a majority of businesses, pretty packaging of a placebo will likely struggle to sustain sales. Perhaps the boom and bust commonly seen with wellness brands isn’t due to the hype cycle, but rather the placebo cycle. |
Posted at 15/4/2024 16:42 by mdi Sounds like during the launch ‘hype cycle’ they got journalists to print headlines that ‘wouldn’‘Thanks to help from marketing firm Jungle Cat Solutions, Ceuta was able to use PR effectively’ ‘The PR was phenomenal,” Connolly commented. “Those headlines just had potency that you would never, ever be able to get in advertising because they just wouldn't be allowed’ Wellness Investors: Beware The Placebo Trap Whats the problem with placebos? Placebo effects tend to wear off, and when they do, your customers will drop off. This forces tremendous spending on acquisition since it can cost five times as much to acquire new customers than keep current ones |
Posted at 15/4/2024 12:43 by mdi Sales of Eroxon apparently £1.7m in April/May, followed by £1.4m in the following 6 months? That revenue deceleration is telling there was a large ‘hype cycle’ that may have misled some men in new launch markets to buy and believe the ‘hype’ around a ‘clinically proven’ placebo hydroalcoholic gel. Especially a gel that was only tested on men who had to already report being able to respond to manual stimulation. But eventually they will run out of new markets to launch to prop up the declining revenue in markets they have launched and the hype is giving way to complaints about being misled?Wellness Investors: Beware The Placebo Trap Whats the problem with placebos? Placebo effects tend to wear off, and when they do, your customers will drop off. This forces tremendous spending on acquisition since it can cost five times as much to acquire new customers than keep current ones. Since repeat customers generate more than half of the revenue for a majority of businesses, pretty packaging of a placebo will likely struggle to sustain sales. Perhaps the boom and bust commonly seen with wellness brands isn’t due to the hype cycle, but rather the placebo cycle. |
Posted at 13/4/2024 14:36 by mdi ‘crikey the CEO would wince at some of the stuff that gets written here - when does being loose with the facts morph into the magic roundabout of make believe’‘For PET500, we estimate that Futura will gain up to 2% of the market in the first five years of launch’ ‘we expect operating profitability to turn positive in 2015 and to rise rapidly from this point in line with the operating leverage, increasing to £9m in 2017’ ‘James Barder has been CEO since 2001. Formerly he was MD of Aon Capital Markets (1995-2001), and he has extensive commercial experience in the reinsurance sector (1977-1989) including firms he founded and co-owned. He first became involved with Futura as an investor in 1997 and joined as chief executive in 2001. He has overall responsibility for all activities of the group, notably shareholder and investor relations matters, licensing and distribution negotiations and new product development activities’ Slightly ironic that those who talk of ‘ the last shred of credibility also want us to believe the CEO is also now qualified to talk about the ‘supposed ‘dosing’ of a non medicated medical device gel which has no active pharmacological ingredients. But yet is supposedly ‘no different’ ‘to viagra dosing’? ‘CEO explains that it can take weeks to months to idenitfy the correct dose of blue pills and even when you have the right dose for your body to adapt to the drug and adapt in the most effective manner. With that context, he explained that they have small tubes to get everyone to have a number of goes at this and allow the body to learn to adapt and respond effectively - in some cases this can take more than the four tubes and he argues this is no different to what customers are doing to adjust to viagra dosing as this also takes time and is not therefore any specifically worse’ Researchers call for stricter rules on drug-like medical devices More oversight is needed over products in the grey area between medical device and medication Powders, tablets and gels used like medications but registered as medical devices the same category plasters and pacemakers fall into need tighter controls, a team of clinical researchers has concluded after studying several such materials. Products that fall into this regulatory grey zone dont need to prove their efficacy or safety in the same way pharmaceuticals do, which could be a concern for vulnerable patients According to European regulations, medical devices are used for diagnosis, prevention or treatment of disease, but unlike drugs their primary mode of action isnt biological. The definition includes everything from medical software to wound dressings and surgical instruments Manufacturers need to demonstrate medical devices safety and performance. An organisation called a notified body then assesses the products conformity and grants it a CE mark. But Van Winckel and her colleagues found only poor clinical evidence for the three devices they investigated. Studies were small or of low quality, often missing placebo controls. Oral powders or gels, sold as medical devices in the European Union (EU), arent regulated to the same safety standards as those applied to medicines As a result, these products, which look like medicines, can be marketed with very limited clinical data and accompanied by poor quality product information. require only certification with a CE (quality) kitemark before the product can be marketed. This process doesnt require evidence of efficacy or safety from high quality clinical trials, as is the case for medicines. It also means that these products can automatically be sold without a prescription across the EU, and actively marketed to patients and clinicians. |
Posted at 13/4/2024 10:31 by mdi Just like the ‘leaky holes’ of how a non medicated hydroalcoholic gel is apparently going to sustain sales estimates annually with repeat customers to be able to meet abs sustain long term the ‘make believe’ future estimates and price targets? Eventually placebos run out of new markets to hype launch into and dupe new customers so as to prop up the flagging sales from whee they already launched in and the majority eventually realise they were duped into buying an expensive placebo. Even if it does continue to work for some if they are convinced to believe the hype and packaging. Sales of Eroxon (or should I say just accounts receivable) apparently £1.7m in April/May, followed by £1.4m in the following 6 months? Didn’t the CEO even mention one hit wonder products that distributors hype and short term and then move on to the next.Wellness Investors: Beware The Placebo Trap Whats the problem with placebos? Placebo effects tend to wear off, and when they do, your customers will drop off. This forces tremendous spending on acquisition since it can cost five times as much to acquire new customers than keep current ones. Since repeat customers generate more than half of the revenue for a majority of businesses, pretty packaging of a placebo will likely struggle to sustain sales. Perhaps the boom and bust commonly seen with wellness brands isn’t due to the hype cycle, but rather the placebo cycle. |
Posted at 11/4/2024 23:11 by mdi Why was the CEO in the Q&A part of the presentation continually looking out the window? At least they did successfully manage in the Q&A not to provide any real or relevant answers. They also eloquently cameup with excuses on why they couldn’t provide any information on repeat sales. Yet they apparently can still definitively claim they have taken a 20% share of the appoved ED treatment market? But then they claim sales are supposedly mostly incremental and they not taking sales from the likes of Viagra or Cialis? Which contradicts the previous statements about capturing a 20% share? But anyway everything else relevant for shareholders who are meant to own the company is apparently subject to ‘commercial sensitivities’ to the benefit of non shareholders. One might even wonder why did they bother fo do a shareholder Q&A? But what was definitely confirmed besides the low cost budget AV setup for shareholders. And is borne out in the balance sheet figures. The distributor and retailer tails (or should that be spelt tales?) are all now apparently wagging this dog. Not the shareholders. Even Stifel are warning most of any Eroxon sales that ever manages to materialise by 2029 based on also applying other many optimistic assumptions ‘will be absorbed by distributors and other middlemen’ Wellness Investors: Beware The Placebo Trap Whats the problem with placebos? Placebo effects tend to wear off, and when they do, your customers will drop off. This forces tremendous spending on acquisition since it can cost five times as much to acquire new customers than keep current ones. Since repeat customers generate more than half of the revenue for a majority of businesses, pretty packaging of a placebo will likely struggle to sustain sales. Perhaps the boom and bust commonly seen with wellness brands isn’t due to the hype cycle, but rather the placebo cycle. |
Posted at 08/1/2024 19:29 by mdi They also did manage to win an award for spending the best big budget on an OTC product. hTtps://www.citeline |
Posted at 18/4/2023 17:44 by lbo Plenty of big sells! looking forward to the fundraising! LOLTherefore, from June 2022 it had roughly 13 months of cash runway it's fair to say the end of the cash runway is in sight FOR EVERY BUYER THERE MUST BE A SELLER Jay: What I meant was, where did the shares you purchased come from? They didn’t come out of thin air. Someone had to sell them to you. The market has two types of investors: individuals like you and me, and institutional investors such as pension funds, mutual funds and hedge funds. Do you believe the seller was more likely another individual investor like you? Or was the seller more likely one of those institutional investors? Haden: I would guess the seller was another individual investor. Jay: That’s incorrect. Since today institutional investors do about 90 percent of all trading, there’s about a 90 percent chance the seller was an institution. Since we now agree the underlying reason you bought the stock was that you believed it would outperform the market, we can also agree the underlying reason the institutional investor sold the stock was that it believed the stock would underperform the market. If that were not the case, it would have continued to hold the stock. Correct? Haden: I guess so. Jay: Okay. You believed it would outperform the market, and the institutional investor believed it would underperform. How many of you can be correct? Haden: Just one. Jay: If you’re re being perfectly honest with yourself, who do you believe had more knowledge about the company”you or the institutional investor? Haden: I’d have to say the institutional investor. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
